Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study

Davis, Mat D.; Ashtamker, Natalia; Steinerman, Joshua R.; Knappertz, Volker

doi:10.1212/nxi.0000000000000327

Cited by 10 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The exposure to high‐efficacy DMT was the only independent predictor of longer time to first relapse. This is not surprising given the differences in efficacy profile and time needed to obtain clinical and MRI benefits reported for the distinct DMT classes 27–29 . This result is also particularly encouraging, as these patients had more severe clinical and MRI disease parameters at onset, compared with patients receiving moderate‐efficacy DMT.…”

Section: Discussionmentioning

confidence: 81%

Early Predictors of 9‐Year Disability in Pediatric Multiple Sclerosis

Meo

Bonacchi

Moiola

et al. 2021

Annals of Neurology

View full text Add to dashboard Cite

The purpose of this study was to assess early predictors of 9-year disability in pediatric patients with multiple sclerosis. Methods: Clinical and magnetic resonance imaging (MRI) assessments of 123 pediatric patients with multiple sclerosis were obtained at disease onset and after 1 and 2 years. A 9-year clinical follow-up was also performed. Cox proportional hazard and multivariable regression models were used to assess independent predictors of time to first relapse and 9-year outcomes. Results: Time to first relapse was predicted by optic nerve lesions (hazard ratio [HR] = 2.10, p = 0.02) and high-efficacy treatment exposure (HR = 0.31, p = 0.005). Predictors of annualized relapse rate were: at baseline, presence of cerebellar (β = −0.15, p < 0.001), cervical cord lesions (β = 0.16, p = 0.003), and high-efficacy treatment exposure (β = −0.14, p = 0.01); considering also 1-year variables, number of relapses (β = 0.14, p = 0.002), and the previous baseline predictors; considering 2-year variables, time to first relapse (2-year: β = −0.12, p = 0.01) entered, whereas high-efficacy treatment exposure exited the model. Predictors of 9-year disability worsening were: at baseline, presence of optic nerve lesions (odds ratio [OR] = 6.45, p = 0.01); considering 1-year and 2-year variables, Expanded Disability Status Scale (EDSS) changes (1-year: OR = 26.05, p < 0.001; 2-year: OR = 16.38, p = 0.02), and ≥ 2 new T2-lesions in 2 years (2-year: OR = 4.91, p = 0.02). Predictors of higher 9-year EDSS score were: at baseline, EDSS score (β = 0.58, p < 0.001), presence of brainstem lesions (β = 0.31, p = 0.04), and number of cervical cord lesions (β = 0.22, p = 0.05); considering 1-year and 2-year variables, EDSS changes (1-year: β = 0.79, p < 0.001; 2-year: β = 0.55, p < 0.001), and ≥ 2 new T2-lesions (1-year: β = 0.28, p = 0.03; 2-year: β = 0.35, p = 0.01). Interpretation: A complete baseline MRI assessment and an accurate clinical and MRI monitoring during the first 2 years of disease contribute to predict 9-year prognosis in pediatric patients with multiple sclerosis.

show abstract

Section: Discussionmentioning

confidence: 81%

Early Predictors of 9‐Year Disability in Pediatric Multiple Sclerosis

Meo

Bonacchi

Moiola

et al. 2021

Annals of Neurology

View full text Add to dashboard Cite

show abstract

“…Glatiramer acetate targets cytokine production and alters the role of T cells 19 . (p2) With a total of 654 participants (193 in the interventional group and 461 in the placebo group) in a study, the patients administered 40 mg/mL 3 times a week for a duration of a year and researchers found that glatiramer acetate at this range had lower relapse rates compared with the patients receiving glatiramer acetate at lower doses 20 …”

Section: Pharmacodynamics: the Mnemonicmentioning

confidence: 99%

“…19(p2) With a total of 654 participants (193 in the interventional group and 461 in the placebo group) in a study, the patients administered 40 mg/mL 3 times a week for a duration of a year and researchers found that glatiramer acetate at this range had lower relapse rates compared with the patients receiving glatiramer acetate at lower doses. 20 As many medication availabilities widen, well-known medications such as glatiramer acetate and interferon beta's (IFN-β's) target effects are contrasted. La Mantia et al 21 presented MRI findings of decreases in thoracic lesions with interferon (IFN) use and decreased brain volume using glatiramer acetate.…”

Section: G = Glatiramer Acetatementioning

confidence: 99%

Using Mnemonic in Management of Multiple Sclerosis

Hussein

Wong

2021

Journal of Neuroscience Nursing

View full text Add to dashboard Cite

BACKGROUND: Multiple sclerosis (MS) is a disease involving demyelination of the central nervous system. Medication management in MS is a vital step in preventing further disease progression. OBJECTIVE: This article presents healthcare providers with an aide-mémoire in the form of a mnemonic to assist in the medication management of MS. METHODS: We explored recent guidelines, systematic reviews, and randomized controlled trials using PubMed, MEDLINE, and CINAHL to analyze the role and efficacy of pharmacotherapy in relapse prevention of MS. CONCLUSION: It is crucial to consider the classifications of MS and its pathophysiology to determine which medication produces the best results. Our proposed mnemonic can support a clinician's recall ability and assist in identifying the respective MS medication.

show abstract

Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis

Gonzalez-Lorenzo,

Ridley,

Minozzi

et al. 2024

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Different therapeutic strategies are available for the treatment of people with relapsing‐remitting multiple sclerosis (RRMS), including immunomodulators, immunosuppressants and biological agents. Although each one of these therapies reduces relapse frequency and slows disability accumulation compared to no treatment, their relative benefit remains unclear. This is an update of a Cochrane review published in 2015. Objectives To compare the efficacy and safety, through network meta‐analysis, of interferon beta‐1b, interferon beta‐1a, glatiramer acetate, natalizumab, mitoxantrone, fingolimod, teriflunomide, dimethyl fumarate, alemtuzumab, pegylated interferon beta‐1a, daclizumab, laquinimod, azathioprine, immunoglobulins, cladribine, cyclophosphamide, diroximel fumarate, fludarabine, interferon beta 1‐a and beta 1‐b, leflunomide, methotrexate, minocycline, mycophenolate mofetil, ofatumumab, ozanimod, ponesimod, rituximab, siponimod and steroids for the treatment of people with RRMS. Search methods CENTRAL, MEDLINE, Embase, and two trials registers were searched on 21 September 2021 together with reference checking, citation searching and contact with study authors to identify additional studies. A top‐up search was conducted on 8 August 2022. Selection criteria Randomised controlled trials (RCTs) that studied one or more of the available immunomodulators and immunosuppressants as monotherapy in comparison to placebo or to another active agent, in adults with RRMS. Data collection and analysis Two authors independently selected studies and extracted data. We considered both direct and indirect evidence and performed data synthesis by pairwise and network meta‐analysis. Certainty of the evidence was assessed by the GRADE approach. Main results We included 50 studies involving 36,541 participants (68.6% female and 31.4% male). Median treatment duration was 24 months, and 25 (50%) studies were placebo‐controlled. Considering the risk of bias, the most frequent concern was related to the role of the sponsor in the authorship of the study report or in data management and analysis, for which we judged 68% of the studies were at high risk of other bias. The other frequent concerns were performance bias (34% judged as having high risk) and attrition bias (32% judged as having high risk). Placebo was used as the common comparator for network analysis. Relapses over 12 months: data were provided in 18 studies (9310 participants). Natalizumab results in a large reduction of people with relapses at 12 months (RR 0.52, 95% CI 0.43 to 0.63; high‐certainty evidence). Fingolimod (RR 0.48, 95% CI 0.39 to 0.57; moderate‐certainty evidence), daclizumab (RR 0.55, 95% CI 0.42 to 0.73; moderate‐certainty evidence), and immunoglobulins (RR 0.60, 95% CI 0.47 to 0.79; moderate‐certainty...

show abstract

Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study

Cited by 10 publications

References 20 publications

Early Predictors of 9‐Year Disability in Pediatric Multiple Sclerosis

Early Predictors of 9‐Year Disability in Pediatric Multiple Sclerosis

Using Mnemonic in Management of Multiple Sclerosis

Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis

Contact Info

Product

Resources

About